Tüdőrák: vizsgálatok itt: Japán

136 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 4. fázisTaking people
  Dabrafenib and/or Trametinib Rollover Study

  Where

  Chuo Ku, Kashiwa

  Életkor

  18 év to 100 év

  People

  100 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT03340506 · EU 2023-509318-13-00
• 2. fázisTaking people
  Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  Where

  Kashiwa

  Életkor

  18 év and over

  People

  430 worldwide

  Run by

  Pfizer

  See details and how to joinNCT04557449 · EU 2024-512120-11-00
• 3. fázisTaking people
  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  Where

  Bunkyo, Chuo Ku, Hidaka, Osaka, Sakai

  Életkor

  18 év and over

  People

  734 worldwide

  Run by

  NovoCure GmbH

  See details and how to joinNCT06216301
• 3. fázisTaking people
  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  Where

  Bunkyo-ku, Fukuoka, Fukushima, Hirakata, Hiroshima, Kashiwa, Kawasaki, Kitaadachi-gun, Kitakyushu, Kobe, Matsuyama, Nagasaki, Niigata, Okayama, Osaka, Sakai, Shinjuku, Tokyo, Yamagata, Yokohama

  Életkor

  18 év and over

  People

  780 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06312137 · EU 2023-508012-35-00
• 3. fázisTaking people
  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Where

  Bunkyo, Chiba, Fukuoka, Hirakata, Hiroshima, Kanazawa, Kashiwa, Kawasaki, Kitaadachi-gun, Kumamoto, Kurume, Matsusaka, Matsuyam, Nagoya, Natori-shi, Niigata, Osaka, Ōta, Ōta-ku, Sapporo, Sendai, Shinjuku, Takatsuki, Toyoake

  Életkor

  18 év and over

  People

  348 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06345729 · EU 2023-507776-42-00
• 3. fázisTaking people
  A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  Where

  Bunkyo-ku, Fukushima, Hamamatsu, Hidaka, Hirakata, Ina-machi, Kanazawa, Kashihara, Kobe, Koto, Kurashiki, Kurume, Matsuyama, Ōsaka-sayama, Sapporo, Sendai, Takatsuki, Yokohama

  Életkor

  18 év and over

  People

  530 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT06646276 · EU 2024-515740-23-00
• 3. fázisTaking people
  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  Where

  Fukuoka, Hokkaido, Ishikawa, Kagoshima, Kanagawa, Kochi, Kyoto, Mie, Miyagi, Osaka, Tokyo, Toyama

  Életkor

  18 év and over

  People

  420 worldwide

  Run by

  GlaxoSmithKline

  See details and how to joinNCT07099898
• 3. fázisTaking people
  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  Where

  Bunkyo, Chiba, Fukuoka, Himeji, Hirakata, Hirosaki, Hiroshima, Kanazawa, Kawasaki, Kobe, Kumamoto, Kurume, Matsusaka, Nagoya, Osaka, Ōta, Ōta-ku, Sakai, Sendai, Shinjuku, Takarazuka, Takatsuki, Tōon, Toyoake, Ureshino, Yokohama

  Életkor

  18 év and over

  People

  675 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07190248 · EU 2024-514500-14-00
• 3. fázisTaking people
  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  Where

  Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama, Nagoya, Niigata, Osaka, Osakasayama-shi, Sendai, Sunto-gun, Yokohama

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07291037 · EU 2024-520101-39-00
• 3. fázisTaking people
  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  Where

  Fukushima, Hirosaki, Kitakyushu, Osaka, Yamagata

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07431827 · EU 2024-517337-41-00
• 3. fázisTaking people
  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  Where

  Aichi, Toyoake, Aomori, Hirosaki, Fukuoka, Fukuoka, Hokkaido, Sapporo, Kagoshima, Kagoshima, Miyagi, Sendai, Osaka, Sakai, Saitama, Hidaka, Shizuoka, Hamamatsu, Tokyo, Chuo-ku, Tokyo, Koto-ku, Wakayama, Wakayama

  Életkor

  18 év and over

  People

  670 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07472517 · EU 2025-520565-51-00
• 3. fázisTaking people
  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  Where

  Kobe, Matsusaka, Ōta, Sapporo, Sendai, Shimotsugagun

  Életkor

  18 év and over

  People

  310 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07554339 · EU 2025-522038-29-00
• 3. fázisTaking people
  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  Where

  Chūōku, Hamamatsu, Hirakata-Shi, Kōtoku, Kurume-Shi, Nagoya, Okayama, Osakasayama-Shi, Sendai, Toon-Shi, Yokohama

  Életkor

  18 év and over

  People

  850 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07680790 · EU 2026-526486-21-00
• 1/2. fázisTaking people
  A Study of DS-3939a in Participants With Solid Tumors

  Where

  Hirakata, Kashiwa-shi, Matsuyama, Sendai, Shiroishi-ku, Sapporo-shi

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT07739966 · EU 2026-525218-75-00
• 1/2. fázisTaking people
  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  Where

  Okayama, Okayama, Osaka, Hirakata, Shizuoka, Sunto-gun

  Életkor

  18 év and over

  People

  55 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07843940 · EU 2026-525459-99-00
• 1. fázisNot yet taking people in Japán
  A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

  Where

  Shizuoka, Tokyo

  Életkor

  18 év and over

  People

  370 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07928258 · EU 2026-526553-33-00
• 3. fázisTaking people
  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  Where

  Akashi, Fukushima, Fukuyama-shi, Gifu, Hamamatsu, Hidaka, Hirakata, Kashihara, Kashiwa, Kitakyushu, Koto, Kurashiki, Kurume, Nagaizumi-cho,Sunto-gun, Nakamura-ku,Nagoya, Nankoku, Natori-shi, Niigata, Osaka, Sagamihara, Sakai, Sapporo, Sendai, Yokohama

  Életkor

  18 év and over

  People

  1000 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT06561386 · EU 2024-513682-40-01
• 3. fázisTaking people
  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  Where

  Chiba, Chūō, Fukuoka, Fukushima, Hirakata, Hiroshima, Kashiwa, Kawasaki, Kitakyushu, Okayama, Osaka, Sakai, Shimotsuga-gun, Shinjuku, Sunto-gun, Wakayama, Yokohama

  Életkor

  18 év and over

  People

  680 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06623422 · EU 2023-506327-29-00
• 2. fázisTaking people
  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  Where

  Osaka, Sakai, Tokyo, Chuo-ku

  Életkor

  18 év and over

  People

  60 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07486817 · EU 2025-523567-38-00
• 3. fázisTaking people
  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  Where

  Fukushima, Kitakyushu, Yamagata

  Életkor

  18 év and over

  People

  876 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07513376 · EU 2025-522643-18-00
• 3. fázisTaking people
  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  Where

  Gifu, Hiroshima, Hyōgo, Ōita

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT07541170 · EU 2025-524263-21-01
• 3. fázisTaking people
  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  Where

  Akashi, Bunkyo-ku, Fukuoka, Hirakata, Hiroshima, Nagaizumi-cho,Sunto-gun, Natori-shi, Niigata, Sakai, Sapporo, Tokyo, Yokohama

  Életkor

  18 év and over

  People

  356 worldwide

  Run by

  Astellas Pharma Global Development, Inc.

  See details and how to joinNCT07566052 · EU 2025-524079-22-00
• No phaseNot yet taking people in Japán
  Real-world Outcome of Zongertinib in Japan (J-HERZ)

  Where

  Tokyo

  Életkor

  18 év and over

  People

  300

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07926308
• 1/2. fázisTaking people
  A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

  Where

  Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama

  Életkor

  12 év and over

  People

  840 worldwide

  Run by

  Nuvalent Inc.

  See details and how to joinNCT05384626 · EU 2024-514266-39-00
• 3. fázisTaking people
  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Where

  Bunkyo-ku, Chiba, Fukuoka, Fukuyama-shi, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kobe, Koto-ku, Kurume-shi, Kyoto, Matsuyama, Nagoya, Natori-shi, Niigata, Okayama, Osaka, Sakai-shi, Sakai-Shi, Sapporo, Sendai, Shimotsuga-gun, Sunto-gun, Takarazuka-shi, Toon-shi, Ube-shi, Wakayama, Yokohama, Yonago-shi

  Életkor

  18 év to 100 év

  People

  750 worldwide

  Run by

  Amgen

  See details and how to joinNCT05920356 · EU 2022-501863-41-00